Patients with respiratory syncytial virus (RSV) hospitalization have increased odds of any acute cardiovascular event ...

A statewide immunization program for infants against respiratory syncytial virus (RSV), which began in 2024, has already ...

Today, the World Health Organization (WHO) published its first-ever position paper on immunization products to protect ...

The incidence of RSV across 5 respiratory virus seasons was substantial among adult patients with high-risk underlying conditions.

Respiratory syncytial virus (RSV) is the number one cause of hospitalization in infants, accounting for about 25% of all ...

Adults with RSV-associated acute respiratory infection face a 2.7-fold higher risk for death within one year, according to a ...

HealthDay News — In a recent study of a population of infants, published online May 6 in Pediatrics, 72% of infants were found to be immunized against respiratory syncytial virus (RSV).

Patients with RSV hospitalization have increased odds of any acute cardiovascular event compared with COVID-19 hospitalizations.

Respiratory syncytial virus (RSV) is the most important cause of infantile bronchiolitis and pneumonia. It is ubiquitous, with most children acquiring their primary infection within the first year ...

Among 69 hospitalisations of infants for respiratory syncytial virus (RSV)–related lower ... The incidence of cases paralleled the RSV epidemic curve, suggesting that the efficacy of nirsevimab ...

These real-world results support the effectiveness of maternal RSV vaccination and could influence policy decisions in other ...